{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:21:36Z","timestamp":1759483296188,"version":"3.40.5"},"reference-count":64,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:p>OBJECTIVE. We undertook a decision analysis to evaluate the economic and health effects and incremental cost-effectiveness of using targeted tuberculin skin testing, compared with universal screening or no screening, before kindergarten.<\/jats:p><jats:p>METHODS. We constructed a decision tree to determine the costs and clinical outcomes of using targeted testing compared with universal screening or no screening. Baseline estimates for input parameters were taken from the medical literature and from California health jurisdiction data. Sensitivity analyses were performed to determine plausible ranges of associated outcomes and costs. We surveyed California health jurisdictions to determine the prevalence of mandatory universal tuberculin skin testing.<\/jats:p><jats:p>RESULTS. In our base-case scenario, the cost to prevent an additional case of tuberculosis by using targeted testing, compared with no screening, was $524897. The cost to prevent an additional case by using universal screening, compared with targeted testing, was $671398. The incremental cost of preventing a case through screening remained above $100000 unless the prevalence of tuberculin skin testing positivity increased to &amp;gt;10%. More than 51% of children entering kindergarten in California live where tuberculin skin testing is mandatory.<\/jats:p><jats:p>CONCLUSIONS. The cost to prevent a case of tuberculosis by using either universal screening or targeted testing of kindergarteners is high. If targeted testing replaced universal tuberculin skin testing in California, then $1.27 million savings per year would be generated for more cost-effective strategies to prevent tuberculosis. Improving the positive predictive value of the risk factor tool or applying it to groups with higher prevalence of latent tuberculosis would make its use more cost-effective. Universal tuberculin skin testing should be discontinued, and targeted testing should be considered only when the prevalence of risk factor positivity and the prevalence of tuberculin skin testing positivity among risk factor\u2013positive individuals are high enough to meet acceptable thresholds for cost-effectiveness.<\/jats:p>","DOI":"10.1542\/peds.2006-2168","type":"journal-article","created":{"date-parts":[[2007,7,2]],"date-time":"2007-07-02T16:35:25Z","timestamp":1183394125000},"page":"90-99","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness of Alternative Strategies for Tuberculosis Screening Before Kindergarten Entry"],"prefix":"10.1542","volume":"120","author":[{"given":"Valerie J.","family":"Flaherman","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis C.","family":"Porco","sequence":"additional","affiliation":[{"name":"California Department of Health Services, Richmond, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot","family":"Marseille","sequence":"additional","affiliation":[{"name":"Health Strategies International, Orinda, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Royce","sequence":"additional","affiliation":[{"name":"California Department of Health Services, Richmond, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2007,7,1]]},"reference":[{"key":"2021120902011968800_R1","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2003"},{"key":"2021120902011968800_R2","unstructured":"US Preventive Services Task Force. Screening for tuberculosis infection. Available at: www.ahrq.gov\/clinic\/uspstf\/uspstubr.htm. Accessed July 1, 2006"},{"key":"2021120902011968800_R3","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med.\u20082000;161:S221\u2013S247","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"2021120902011968800_R4","doi-asserted-by":"crossref","unstructured":"Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics.\u20082004;114:1175\u20131201","DOI":"10.1542\/peds.2004-0809"},{"key":"2021120902011968800_R5","doi-asserted-by":"crossref","unstructured":"Saiman L, San Gabriel P, Schulte J, Vargas MP, Kenyon T, Onorato I. Risk factors for latent tuberculosis infection among children in New York City. Pediatrics.\u20082001;107:999\u20131003","DOI":"10.1542\/peds.107.5.999"},{"key":"2021120902011968800_R6","doi-asserted-by":"crossref","unstructured":"Besser RE, Pakiz B, Schulte JM, et al. Risk factors for positive Mantoux tuberculin skin tests in children in San Diego, California: evidence for boosting and possible foodborne transmission. Pediatrics.\u20082001;108:305\u2013310","DOI":"10.1542\/peds.108.2.305"},{"key":"2021120902011968800_R7","doi-asserted-by":"crossref","unstructured":"Froehlich H, Ackerson LM, Morozumi PA. Targeted testing of children for tuberculosis: validation of a risk assessment questionnaire. Pediatrics.\u20082001;107(4). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/4\/e54","DOI":"10.1542\/peds.107.4.e54"},{"key":"2021120902011968800_R8","doi-asserted-by":"crossref","unstructured":"Ozuah PO, Ozuah TP, Stein RE, Burton W, Mulvihill M. Evaluation of a risk assessment questionnaire used to target tuberculin skin testing in children. JAMA.\u20082001;285:451\u2013453","DOI":"10.1001\/jama.285.4.451"},{"key":"2021120902011968800_R9","doi-asserted-by":"crossref","unstructured":"Hsu K, Christiansen D, O'Connor D, Bernardo J, Hacker K. Self-assessment of tuberculosis infection risk by urban adolescents. Arch Pediatr Adolesc Med.\u20082003;157:1227\u20131231","DOI":"10.1001\/archpedi.157.12.1227"},{"key":"2021120902011968800_R10","doi-asserted-by":"crossref","unstructured":"Pong AL, Anders BJ, Moser KS, Starkey M, Gassmann A, Besser RE. Tuberculosis screening at 2 San Diego high schools with high-risk populations. Arch Pediatr Adolesc Med.\u20081998;152:646\u2013650","DOI":"10.1001\/archpedi.152.7.646"},{"key":"2021120902011968800_R11","doi-asserted-by":"crossref","unstructured":"Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med.\u20081998;158:1871\u20131875","DOI":"10.1164\/ajrccm.158.6.9804106"},{"key":"2021120902011968800_R12","doi-asserted-by":"crossref","unstructured":"Mohle-Boetani JC, Miller B, Halpern M, et al. School-based screening for tuberculous infection: a cost-benefit analysis. JAMA.\u20081995;274:613\u2013619","DOI":"10.1001\/jama.274.8.613"},{"key":"2021120902011968800_R13","doi-asserted-by":"crossref","unstructured":"Gounder CR, Driver CR, Scholten JN, Shen H, Munsiff SS. Tuberculin testing and risk of tuberculosis infection among New York City schoolchildren. Pediatrics.\u20082003;111(4). Available at: www.pediatrics.org\/cgi\/content\/full\/111\/4\/e309","DOI":"10.1542\/peds.111.4.e309"},{"key":"2021120902011968800_R14","doi-asserted-by":"crossref","unstructured":"Driver CR, Valway SE, Cantwell MF, Onorato IM. Tuberculin skin test screening in schoolchildren in the United States. Pediatrics.\u20081996;98:97\u2013102","DOI":"10.1542\/peds.98.1.97"},{"key":"2021120902011968800_R15","doi-asserted-by":"crossref","unstructured":"Miller TL, Hilsenrath P, Lykens K, McNabb SJ, Moonan PK, Weis SE. Using cost and health impacts to prioritize the targeted testing of tuberculosis in the United States. Ann Epidemiol.\u20082006;16:305\u2013312","DOI":"10.1016\/j.annepidem.2005.07.053"},{"key":"2021120902011968800_R16","unstructured":"US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available at: www.bls.gov\/cpi\/home.htm. Accessed May 5, 2006"},{"key":"2021120902011968800_R17","unstructured":"Steele GL. Common Lisp: The Language. 2nd ed. Bedford, MA: Digital Press; 1990"},{"key":"2021120902011968800_R18","unstructured":"National Tuberculosis Controllers Association. Guidelines for the investigation of contacts of persons with infectious tuberculosis. MMWR Recomm Rep.\u20082005;54(RR-15):1\u201347"},{"key":"2021120902011968800_R19","unstructured":"Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?Int J Tuberc Lung Dis.\u20081999;3:847\u2013850"},{"key":"2021120902011968800_R20","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ.\u20081982;60:555\u2013564"},{"key":"2021120902011968800_R21","doi-asserted-by":"crossref","unstructured":"Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med.\u20082000;162:2079\u20132086","DOI":"10.1164\/ajrccm.162.6.2001111"},{"key":"2021120902011968800_R22","unstructured":"Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc.\u20081970;26:28\u2013106"},{"key":"2021120902011968800_R23","doi-asserted-by":"crossref","unstructured":"Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making.\u20082000;20:332\u2013342","DOI":"10.1177\/0272989X0002000310"},{"key":"2021120902011968800_R24","doi-asserted-by":"crossref","unstructured":"Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother.\u20082004;53:558\u2013561","DOI":"10.1093\/jac\/dkh142"},{"key":"2021120902011968800_R25","doi-asserted-by":"crossref","unstructured":"Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life?And why doesn't it increase with inflation? Arch Intern Med.\u20082003;163:1637\u20131641","DOI":"10.1001\/archinte.163.14.1637"},{"key":"2021120902011968800_R26","doi-asserted-by":"crossref","unstructured":"Villarino ME, Burman W, Wang YC, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA.\u20081999;281:169\u2013171","DOI":"10.1001\/jama.281.2.169"},{"key":"2021120902011968800_R27","doi-asserted-by":"crossref","unstructured":"Rose DN, Schechter CB, Adler JJ. Interpretation of the tuberculin skin test. J Gen Intern Med.\u20081995;10:635\u2013642","DOI":"10.1007\/BF02602749"},{"key":"2021120902011968800_R28","unstructured":"Berkel GM, Cobelens FG, de Vries G, Draayer-Jansen IW, Borgdorff MW. Tuberculin skin test: estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis.\u20082005;9:310\u2013316"},{"key":"2021120902011968800_R29","doi-asserted-by":"crossref","unstructured":"Huebner RE, Schein MF, Cauthen GM, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis.\u20081992;145:1160\u20131166","DOI":"10.1164\/ajrccm\/145.5.1160"},{"key":"2021120902011968800_R30","unstructured":"Sepulveda RL, Burr C, Ferrer X, Sorensen RU. Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with bacillus Calmette-Guerin at birth in Santiago, Chile. Pediatr Infect Dis J.\u20081988;7:578\u2013581"},{"key":"2021120902011968800_R31","doi-asserted-by":"crossref","unstructured":"Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size?Clin Infect Dis.\u20082005;40:211\u2013217","DOI":"10.1086\/426434"},{"key":"2021120902011968800_R32","doi-asserted-by":"crossref","unstructured":"Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics.\u20081965;36:624\u2013627","DOI":"10.1542\/peds.36.4.624"},{"key":"2021120902011968800_R33","unstructured":"US Department of Health and Human Services. Part B Extract Summary System (BESS) data file. Available at: www.cms.hhs.gov\/NonIdentifiableDataFiles\/03_PartBExtractSummarySystem.asp. Accessed June 25, 2006"},{"key":"2021120902011968800_R34","unstructured":"US Department of Labor. November 2004 employment and wage estimates. Available at: www.bls.gov\/oes\/oes_2004_n.htm. Accessed May 6, 2006"},{"key":"2021120902011968800_R35","unstructured":"Thomson Corp. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR; 2004;111"},{"key":"2021120902011968800_R36","doi-asserted-by":"crossref","unstructured":"Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA.\u20081999;281:1014\u20131018","DOI":"10.1001\/jama.281.11.1014"},{"key":"2021120902011968800_R37","unstructured":"Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis.\u20081978;117:991\u20131001"},{"key":"2021120902011968800_R38","unstructured":"Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med.\u20081996;164:486\u2013491"},{"key":"2021120902011968800_R39","doi-asserted-by":"crossref","unstructured":"O'Brien RJ, Long MW, Cross FS, Lyle MA, Snider DE Jr. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics.\u20081983;72:491\u2013499","DOI":"10.1542\/peds.72.4.491"},{"key":"2021120902011968800_R40","doi-asserted-by":"crossref","unstructured":"Stein MT, Liang D. Clinical hepatotoxicity of isoniazid in children. Pediatrics.\u20081979;64:499\u2013505","DOI":"10.1542\/peds.64.4.499"},{"key":"2021120902011968800_R41","doi-asserted-by":"crossref","unstructured":"Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med.\u20081996;154:1013\u20131019","DOI":"10.1164\/ajrccm.154.4.8887600"},{"key":"2021120902011968800_R42","doi-asserted-by":"crossref","unstructured":"Snyder DC, Chin DP. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med.\u20081999;160:582\u2013586","DOI":"10.1164\/ajrccm.160.2.9901049"},{"key":"2021120902011968800_R43","doi-asserted-by":"crossref","unstructured":"Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest.\u20081997;112:63\u201370","DOI":"10.1378\/chest.112.1.63"},{"key":"2021120902011968800_R44","unstructured":"Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis.\u20082000;4:931\u2013939"},{"key":"2021120902011968800_R45","unstructured":"Sprinson JE, Flood J, Fan CS, et al. Evaluation of tuberculosis contact investigations in California. Int J Tuberc Lung Dis.\u20082003;7(suppl 3):S363\u2013S368"},{"key":"2021120902011968800_R46","unstructured":"Daley CL. Tuberculosis latency in humans. In: Rom WN, Garay SM, eds. Tuberculosis. 2nd ed. Philadelphia, PA: Lippincott Williams & Williams; 2004:85\u201399"},{"key":"2021120902011968800_R47","doi-asserted-by":"crossref","unstructured":"McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis.\u20082005;41:1125\u20131133","DOI":"10.1086\/444463"},{"key":"2021120902011968800_R48","doi-asserted-by":"crossref","unstructured":"Lichtenberg F. The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-Level Evidence From 1997\u20132003. New York, NY: Columbia University and National Bureau of Economic Research; 2005","DOI":"10.2165\/00019053-200624003-00002"},{"key":"2021120902011968800_R49","unstructured":"State of California, Department of Finance. Race\/Ethnic Population With Age and Sex Detail, 2000\u20132050. Sacramento, CA: State of California, Department of Finance; 2004"},{"key":"2021120902011968800_R50","unstructured":"County of Los Angeles. TB Cases Identified Through School Mandate TB Screening Activities in LAC Public Health Centers for Mandate Years 93\u201394 through 98\u201399. Los Angeles, CA: County of Los Angeles; 2001"},{"key":"2021120902011968800_R51","doi-asserted-by":"crossref","unstructured":"Starke JR. Tuberculosis in children. Semin Respir Crit Care Med.\u20082004;25:353\u2013364","DOI":"10.1055\/s-2004-829507"},{"key":"2021120902011968800_R52","unstructured":"Stout JE, Nageswaran S, Tilson E. Effectiveness of a tuberculosis screening questionnaire in identifying children with latent tuberculosis infection. Presented at: annual meeting of the American Thoracic Society; May 22, 2005; San Diego, CA"},{"key":"2021120902011968800_R53","unstructured":"County of Los Angeles. Analysis of Results From the Mandated School TB Skin Test, 2004\u20132005, All Schools. Los Angeles, CA: County of Los Angeles; 2005"},{"key":"2021120902011968800_R54","doi-asserted-by":"crossref","unstructured":"LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med.\u20082003;168:443\u2013447","DOI":"10.1164\/rccm.200303-390OC"},{"key":"2021120902011968800_R55","doi-asserted-by":"crossref","unstructured":"Chang S, Wheeler LS, Farrell KP. Public health impact of targeted tuberculosis screening in public schools. Am J Public Health.\u20082002;92:1942\u20131945","DOI":"10.2105\/AJPH.92.12.1942"},{"key":"2021120902011968800_R56","unstructured":"Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis.\u20082000;4:895\u2013903"},{"key":"2021120902011968800_R57","doi-asserted-by":"crossref","unstructured":"Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol.\u20081974;99:131\u2013138","DOI":"10.1093\/oxfordjournals.aje.a121593"},{"key":"2021120902011968800_R58","doi-asserted-by":"crossref","unstructured":"Pope AS, Sartwell PE, Zacks D. Development of tuberculosis in infected children. Tuberculosis.\u20081939;29:1318\u20131326","DOI":"10.2105\/AJPH.29.12.1318"},{"key":"2021120902011968800_R59","doi-asserted-by":"crossref","unstructured":"Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. Am Rev Respir Dis.\u20081988;137:805\u2013809","DOI":"10.1164\/ajrccm\/137.4.805"},{"key":"2021120902011968800_R60","doi-asserted-by":"crossref","unstructured":"Fine PE, Sterne JA, Ponnighaus JM, Rees RJ. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet.\u20081994;344:1245\u20131249","DOI":"10.1016\/S0140-6736(94)90748-X"},{"key":"2021120902011968800_R61","unstructured":"Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis.\u20081967;95:935\u2013943"},{"key":"2021120902011968800_R62","unstructured":"Ferebee S, Mount FW, Anastasiades A. Prophylactic effects of isoniazid on primary tuberculosis in children: a preliminary report. Am Rev Tuberc.\u20081957;76:942\u2013963"},{"key":"2021120902011968800_R63","doi-asserted-by":"crossref","unstructured":"Hsu KH. Thirty years after isoniazid: its impact on tuberculosis in children and adolescents. JAMA.\u20081984;251:1283\u20131285","DOI":"10.1001\/jama.251.10.1283"},{"key":"2021120902011968800_R64","doi-asserted-by":"crossref","unstructured":"Leung CC, Yew WW, Chang KC, et al. Risk of active tuberculosis among schoolchildren in Hong Kong. Arch Pediatr Adolesc Med.\u20082006;160:247\u2013251","DOI":"10.1001\/archpedi.160.3.247"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/90\/1119972\/zpe00707000090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/90\/1119972\/zpe00707000090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T20:30:43Z","timestamp":1683923443000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/120\/1\/90\/70604\/Cost-effectiveness-of-Alternative-Strategies-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,7,1]]},"published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-2168","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}